

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 May 2024 (16.05.2024)



(10) International Publication Number
WO 2024/102672 A2

- (51) International Patent Classification:
C12N 15/861 (2006.01) A61K 31/711 (2006.01)
- (21) International Application Number:
PCT/US2023/078864
- (22) International Filing Date:
06 November 2023 (06.11.2023)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/423,481 07 November 2022 (07.11.2022) US
- (71) Applicant: OCUGEN, INC. [US/US]; 11 Great Valley
Parkway, Malvern, PA 19355 (US).
- (72) Inventor: UPADHYAY, Arun, Kumar; 403 Blue Welsh
St., Malvern, PA 19355 (US).
- (74) Agent: CHA, Don, D.; 14405 W Colfax Ave, Suite 305,
Lakewood, CO 80228 (US).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF NEUROLOGICAL DISORDER USING NHR




FIG. 1

(57) Abstract: The present disclosure provides methods for ameliorating or treating a neurological condition or disease in a subject in need of treatment thereof by administering to the subject a therapeutically effective amount of a composition comprising (i) a recombinant DNA (rDNA), wherein the rDNA comprises a human nuclear hormone receptor (hNHR) gene or a fragment thereof; and (ii) a delivery vehicle adapted for delivering said rDNA to neurological cells or tissues to ameliorate or treat said neurological condition or disease.

[Continued on next page]

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*